У нас вы можете посмотреть бесплатно Webinar: Digital twins for drug repurposing by integrating mathematical modelling and ML или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
The rapid development of computational approaches has revolutionised the field of drug discovery and repurposing. Here I will show a practical application of digital twins built by the synergistic combination of mathematical modelling of the cell and machine learning techniques to identify potential drug candidates for repurposing and subsequently validate their efficacy using real-world data. After discussing the inherent challenges associated with traditional drug discovery methods and the need for alternative approaches I will introduce the concept of digital twins, virtual replicas of real biological systems, which leverage mathematical models to capture the intricacies of cellular behaviour and response to drugs. By integrating machine learning algorithms, these digital twins can be trained on vast datasets to predict drug effectiveness and identify promising candidates for repurposing. Moreover, I will emphasise the importance of validating these predictions with real-world data, obtained from biomedical databases, to ensure reliability and efficacy. The presentation aims to showcase the power of integrating mathematical modelling, digital twins, and machine learning for drug repurposing, paving the way for accelerated and cost-effective drug discovery processes. Speaker: Joaquín Dopazo, Andalusian Platform for Computational Medicine, Fundación Progreso y Salud, Hospital Virgen del Rocío (Sevilla, Spain) All materials are free cultural works licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, except where further licensing details are provided.